Kayne Anderson Rudnick Investment Management
ALNY icon

Kayne Anderson Rudnick Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Kayne Anderson Rudnick Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.23K Buy
7
+5
+250% +$1.51K ﹤0.01% 846
2026
Q1 		$662 Sell
2
-1
-33% -$340 ﹤0.01% 880
2025
Q4 		$1.44K Buy
3
+1
+50% +$443 ﹤0.01% 847
2025
Q3 		$1.23K Sell
2
-3
-60% -$1.22K ﹤0.01% 865
2025
Q2 		$1.86K Buy
+5
New +$1.38K ﹤0.01% 858
2025
Q1 		– Sell
-4
Closed -$1.07K – 966
2024
Q4 		$1.07K Buy
+4
New +$1.05K ﹤0.01% 878
2024
Q2 		– Sell
-4
Closed -$598 – 999
2024
Q1 		$598 Hold
4
– – ﹤0.01% 897
2023
Q4 		$766 Hold
4
– – ﹤0.01% 856
2023
Q3 		$708 Hold
4
– – ﹤0.01% 767
2023
Q2 		$760 Buy
+4
New +$793 ﹤0.01% 771
2022
Q2 		– Sell
-9
Closed -$1K – 603
2022
Q1 		$1K Buy
+9
New +$1.37K ﹤0.01% 615
2021
Q1 		– Sell
-6
Closed -$1K – 564
2020
Q4 		$1K Buy
+6
New +$801 ﹤0.01% 566

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management's ALNY Position: Q2 2026 in Review

Kayne Anderson Rudnick Investment Management increased its Alnylam Pharmaceuticals (ALNY) stake by 250% in Q2 2026, buying an estimated $1.51K and bringing the position to 7 shares worth $2.23K. The position accounts for ﹤0.01% of the portfolio, ranked #846.

Kayne Anderson Rudnick Investment Management first reported a position in ALNY in Q4 2020 and has held it in 12 quarters since. 788 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Kayne Anderson Rudnick Investment Management held 7 shares of Alnylam Pharmaceuticals worth $2.23K as of Q2 2026.
  • Kayne Anderson Rudnick Investment Management bought 5 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $1.51K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Kayne Anderson Rudnick Investment Management's portfolio in Q2 2026, its #846 holding.
  • Kayne Anderson Rudnick Investment Management first reported a position in Alnylam Pharmaceuticals in Q4 2020 and has held it in 12 quarters since.
  • 788 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q2 2026, filed 13 Aug 2026.